Categories: Health

Voting Rights and Shares Capital of the Company

Published by
Globe News Wire


In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Dec. 08, 2022 (GLOBE NEWSWIRE) —

Paris, France, December 8, 2022
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date Number of Shares Outstanding Total number of voting rights
Total voting rights, theoretical (1) Total voting rights,
exercisable (2)
November 30, 2022 34,875,872 36,286,699 36,269,556

(1) The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers. 

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter. 

Contacts

Nanobiotix

Nanobiotix Communications
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com

Nanobiotix Investor Relations
Kate McNeil
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com

Media Relations

France – Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com

LifeSci Advisors 
Ligia Vela-Reid 
+44 (0) 7413825310 
lvela-reid@lifesciadvisors.com 

 

Globe News Wire
Share
Published by
Globe News Wire

Recent Posts

AERWINS Technologies Inc. and PONO Capital Corp. Complete

HONOLULU and TOKYO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- AERWINS Technologies Inc. (“AERWINS” or the… Read More

50 mins ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals,… Read More

51 mins ago

Sarissa Capital Highlights Amarin’s Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin

Sarissa launches website www.freeamarin.com and posts presentation for shareholders Sarissa urges shareholders to vote the… Read More

52 mins ago

Miner Orb Introduces a New, Secure Way of Purchasing

Nevada, Texas, United States, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Summary: Miner Orb has emerged as… Read More

2 hours ago

Arcutis Biotherapeutics Reports Inducement Grants Under

WESTLAKE VILLAGE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early… Read More

2 hours ago

Firsthand Technology Value Fund Discloses Preliminary NAV of $4.44 Per Share as of December 31, 2022

Top Holdings Include IntraOp Medical, Wrightspeed, Hera Systems, Revasum, and EQX Capital SAN JOSE, Calif.--(BUSINESS… Read More

2 hours ago